Con el objetivo de abordar las necesidades médicas no cubiertas relacionadas con la COVID-19, se financiarán proyectos de investigación individuales, bien definidos, que aborden alguna de las siguientes áreas:
- Expand data on clinical course and outcome in vulnerable populations:
- Immune suppressed, specifically- HIV, cancer chronic inflammatory conditions (i.e., RA or IBD), and chronic liver disease, pre-existing pulmonary disease.
- Residents of long-term care facilities/nursing homes, and older adults.
- At risk for healthcare disparities (e.g. Black/African American, socio-economic class).
- Long-term sequelae (i.e., pulmonary fibrosis, neurologic, cardiac, quality of life).
- Real world safety and effectiveness of remdesivir used alone or with other agents (JAK inhibitors, IL-6 inhibitors, convalescent plasma and ACE inhibitors and ARBs):
- Viral kinetics and clinical outcomes.
- Based on duration of treatment (e.g., 5 vs 10 days, shorter courses).
- Use in early (non-severe) disease.
- Course completion in alternative (non-inpatient setting) or alternative treatment pathways.